319 related articles for article (PubMed ID: 34475102)
1. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pollack SM; Redman MW; Baker KK; Wagner MJ; Schroeder BA; Loggers ET; Trieselmann K; Copeland VC; Zhang S; Black G; McDonnell S; Gregory J; Johnson R; Moore R; Jones RL; Cranmer LD
JAMA Oncol; 2020 Nov; 6(11):1778-1782. PubMed ID: 32910151
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study.
Liu Z; Liu C; Yao W; Gao S; Wang J; Zhang P; Ge H
Anticancer Drugs; 2021 Oct; 32(9):962-968. PubMed ID: 34001702
[TBL] [Abstract][Full Text] [Related]
5. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
6. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial.
Tian Z; Dong S; Zuo W; Li P; Zhang F; Gao S; Yang Y; Li C; Zhang P; Wang X; Wang J; Yao W
Front Pharmacol; 2022; 13():987569. PubMed ID: 36582535
[No Abstract] [Full Text] [Related]
8. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
13. Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
Liu X; Jiang S; Wang H; Wu X; Yan W; Chen Y; Xu Y; Wang C; Yao W; Wang J; Yu L; Miao J; Chen H; Xia J; Huang M; Zhang X; Luo Z
Clin Cancer Res; 2022 Dec; 28(24):5280-5289. PubMed ID: 36239473
[TBL] [Abstract][Full Text] [Related]
14. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
16. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Schöffski P; Bahleda R; Wagner AJ; Burgess MA; Junker N; Chisamore M; Peterson P; Szpurka AM; Ceccarelli M; Tap WD
Clin Cancer Res; 2023 Sep; 29(17):3320-3328. PubMed ID: 37382656
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
20. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
